angie lackenby
angie lackenby
Clinical Scientist, UK Health Security Agency
Verified email at
Cited by
Cited by
Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity
E Volz, V Hill, JT McCrone, A Price, D Jorgensen, ┴ O’Toole, J Southgate, ...
Cell 184 (1), 64-75. e11, 2021
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ...
The Lancet Infectious Diseases 22 (1), 35-42, 2022
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinalá…
A Singanayagam, S Hakki, J Dunning, KJ Madon, MA Crone, A Koycheva, ...
The lancet infectious diseases 22 (2), 183-195, 2022
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ...
The Lancet 397 (10286), 1725-1735, 2021
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ...
The Lancet 397 (10283), 1459-1469, 2021
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season
A Meijer, A Lackenby, O Hungnes, B Lina, S Van Der Werf, B Schweiger, ...
Emerging infectious diseases 15 (4), 552, 2009
Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe
A Lackenby, O Hungnes, SG Dudman, A Meijer, WJ Paget, AJ Hay, ...
Eurosurveillance 13 (5), 3-4, 2008
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7
B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ...
Cell reports 35 (13), 2021
Late Ebola virus relapse causing meningoencephalitis: a case report
M Jacobs, A Rodger, DJ Bell, S Bhagani, I Cropley, A Filipe, RJ Gifford, ...
The Lancet 388 (10043), 498-503, 2016
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study
MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ...
The Lancet Public Health 6 (5), e335-e345, 2021
The mechanism of resistance to favipiravir in influenza
DH Goldhill, AJW Te Velthuis, RA Fletcher, P Langat, M Zambon, ...
Proceedings of the National Academy of Sciences 115 (45), 11613-11618, 2018
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08
SH Hauge, S Dudman, K Borgen, A Lackenby, O Hungnes
Emerging infectious diseases 15 (2), 155, 2009
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives
AC Hurt, T Chotpitayasunondh, NJ Cox, R Daniels, AM Fry, LV Gubareva, ...
The Lancet infectious diseases 12 (3), 240-248, 2012
Neuraminidase receptor binding variants of human influenza A (H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
YP Lin, V Gregory, P Collins, J Kloess, S Wharton, N Cattle, A Lackenby, ...
Journal of virology 84 (13), 6769-6781, 2010
Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children
I Stephenson, J Democratis, A Lackenby, T McNally, J Smith, M Pareek, ...
Clinical Infectious Diseases 48 (4), 389-396, 2009
The potential impact of neuraminidase inhibitor resistant influenza
A Lackenby, CI Thompson, J Democratis
Current opinion in infectious diseases 21 (6), 626-638, 2008
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
E Takashita, A Meijer, A Lackenby, L Gubareva, H Rebelo-de-Andrade, ...
Antiviral research 117, 27-38, 2015
Variation in the ability of human influenza A viruses to induce and inhibit the IFN-β pathway
A Hayman, S Comely, A Lackenby, S Murphy, J McCauley, S Goodbourn, ...
Virology 347 (1), 52-64, 2006
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015
AC Hurt, TG Besselaar, RS Daniels, B Ermetal, A Fry, L Gubareva, ...
Antiviral research 132, 178-185, 2016
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017
A Lackenby, TG Besselaar, RS Daniels, A Fry, V Gregory, LV Gubareva, ...
Antiviral research 157, 38-46, 2018
The system can't perform the operation now. Try again later.
Articles 1–20